BLT CEO and Founder Dr. Nick Hartnell discusses his work developing an off-the-shelf, biological soft-tissue product derived from kangaroo tails to solve key limitations in current graft options.
In an interview with SmartTRAK at the American Orthopaedic Society for Sports Medicine (AOSSM), BLT’s Founder and CEO Dr. Nick Hartnell discusses the innovative product his company has developed – an off-the-shelf, biological soft tissue xenograft derived from kangaroo tails.
To listen to the interview, click on the following video (4:15 min). A link to download a complete transcript of the interview is also provided below.
SmartTRAK: Hi, this is Emily Meng. Today I'm here at AOSSM, and I'm with Nick Hartnell with BLT. Welcome, Nick.
Dr. Nick Hartnell: Thank you. Thank you for having me.
So why don't you tell us a little bit about your background and your product?
NH: Great, thanks. Well, I'm a knee surgeon. I'm from country New South Wales in Australia, and I do lots of soft tissue reconstruction. And when I was doing my surgery, I realized there was this hole in the market, in that we need soft tissue, we need to be able to replace or reconstruct soft tissue with something biological. And the options were taking the graft from that person, or autograft, take an allograft, so from cadavers. But the cadaver tissue is not so strong. It needs to be deep-frozen. And I wanted to come up with something that was off-the-shelf that the surgeon could use whenever they needed it.
So what I've been working on in the last 10 years is getting a product which is off the shelf, which is based on the kangaroo. Now the kangaroo, as you can imagine, is one of the most athletic animals I believe in the world, but certainly in Australia. And the kangaroo, we've proven, has such beautiful soft tissue. So what we've been able to do is ...
Interested in learning more about BLT’s off-the-shelf biological soft tissue xenograft derived from kangaroo tails? Click the button below to access the full transcript of SmartTRAK Orthobiologics Analyst Emily Meng’s interview with BLT CEO and Founder Dr. Nick Hartnell.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to mkt experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase efficiency, improve productivity and reduce costs for your company, just click here.
